Nuvectis Pharma, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate
Nuvectis Pharma, Inc. (NVCT) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate of 4.09% for the 9-month period ending 2023-09-30, per its 10-Q filed 2023-11-08.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate · last filed 2023-11-08
- Nuvectis Pharma, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2023-03-31 was 4.09%, a 129.78% increase year-over-year.
- Nuvectis Pharma, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2022-03-31 was 1.78%.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 9 month |
|---|---|---|---|
| 2023-09-30 | 4.09% 10-Q · filed 2023-11-08 | ||
| 2023-06-30 | 4.09% 10-Q · filed 2023-08-09 | ||
| 2023-03-31 | 4.09% 10-Q · filed 2023-05-10 | ||
| 2022-06-30 | 1.78% 10-Q · filed 2022-08-10 | ||
| 2022-03-31 | 1.78% 10-Q · filed 2022-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 |